TScan Therapeutics, Inc. (NasdaqGM: TCRX)
Health Care · Biotechnology · US
$0.28
-13.60% today · -84.4% 1Y
TScan Therapeutics, Inc. (NasdaqGM: TCRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $21.72M and employs 138 people.
Over the last twelve months the share price has lost 84.4%, trading between 0.29 and 2.57.
Tweenvest scores TScan Therapeutics, Inc. across four factors: quality 35/100, value 46/100, growth 100/100. Its strongest factor is growth.
TCRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $21.72M
- Revenue (TTM)
- $7.11M
- P/E
- —
- EPS
- -1.74
- Dividend yield
- —
- Beta (5Y)
- 1.14
- 52-week high
- $2.57
- 52-week low
- $0.29
- Avg volume (3M)
- —
- Shares outstanding
- 67.78M
- Employees
- 138
- Next earnings
- —
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- ISIN
- US89854M1018
- Founded
- 2018
- Listed since
- Jul 16, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GenSight Biologics S.A.ENXTPA: SIGHT | $22.09M | €0.08 | -4.78% |
| Arterra Bioscience S.p.A.BIT: ARBS | $22.06M | €3.08 | +4.05% |
| Helyx Industries S.p.A.BIT: HLX | $21.81M | €0.76 | +2.15% |
| Resverlogix Corp.TSX: RVX | $21.74M | CA$0.09 | -5.56% |
| Modalis Therapeutics CorporationTSE: 4883 | $21.60M | ¥32.00 | -3.03% |
| Quoin Pharmaceuticals, Ltd.NasdaqCM: QNRX | $21.47M | $4.43 | -0.89% |
| Medicure Inc.TSXV: MPH | $21.38M | CA$3.00 | +2.74% |
| Xbrane Biopharma AB (publ)OM: XBRANE | $21.35M | Skr12.85 | +23.56% |
Figures last refreshed Oct 4, 2026.